id: NEW:phenobarbital_treatment_to_NEW:hospital_length_of_stay_aws
name: Phenobarbital Treatment for Alcohol Withdrawal â†’ Hospital Length of Stay for
  Alcohol Withdrawal Syndrome
from_node:
  node_id: NEW:phenobarbital_treatment
  node_name: Phenobarbital Treatment for Alcohol Withdrawal
to_node:
  node_id: NEW:hospital_length_of_stay_aws
  node_name: Hospital Length of Stay for Alcohol Withdrawal Syndrome
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Chronic alcohol use leads to downregulation of GABA receptors, causing
  benzodiazepine resistance in many patients with alcohol withdrawal syndrome'
- 'Step 2: Phenobarbital acts on GABA-A receptors through a different binding site
  than benzodiazepines, providing effective symptom control even in benzodiazepine-resistant
  patients'
- 'Step 3: More effective withdrawal symptom management with phenobarbital leads to
  faster clinical stabilization and reduced need for escalating benzodiazepine doses'
- 'Step 4: Faster symptom resolution and clinical stability enables earlier hospital
  discharge, reducing overall hospital length of stay by approximately 2.6 days compared
  to benzodiazepine-only treatment'
evidence:
  quality_rating: A
  n_studies: 8
  primary_citation: 'Zaryab Umar et al. 2023. "Phenobarbital and Alcohol Withdrawal
    Syndrome: A Systematic Review and Meta-Analysis." Cureus.'
  supporting_citations: []
description: 'Phenobarbital treatment for alcohol withdrawal syndrome is associated
  with a statistically significant reduction in hospital length of stay compared to
  benzodiazepine-only treatment. This meta-analysis found a mean difference of -2.6
  days (95% CI: -4.48 to -0.72, p=0.007) favoring phenobarbital. The mechanism involves
  phenobarbital''s ability to effectively manage withdrawal symptoms through GABA-A
  receptor modulation, particularly in patients who are resistant to benzodiazepines
  due to chronic alcohol-induced GABA receptor downregulation.'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: -2.6
    type: mean_difference_days
    ci_lower: -4.48
    ci_upper: -0.72
  p_value: 0.007
  sample_size: null
moderators:
- name: Symptom severity
  direction: strengthens
  strength: moderate
  description: Drug administration should be adapted according to the severity of
    symptoms; more severe cases may show greater benefit from phenobarbital
- name: Benzodiazepine resistance
  direction: strengthens
  strength: moderate
  description: Patients with downregulated GABA receptors and benzodiazepine resistance
    may benefit more from phenobarbital's alternative mechanism of action
- name: Phenobarbital dosing protocol
  direction: weakens
  strength: weak
  description: Lack of uniformity in phenobarbital dosing across studies may affect
    consistency of outcomes
